208 related articles for article (PubMed ID: 33851364)
1. Successful treatment of an adult patient with diffuse midline glioma employing olaparib combined with bevacizumab.
Wang Y; Xu J; Luo N; Qi C; Tao R
Invest New Drugs; 2021 Oct; 39(5):1432-1435. PubMed ID: 33851364
[TBL] [Abstract][Full Text] [Related]
2. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
[TBL] [Abstract][Full Text] [Related]
3. Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
Vergote I; Ray-Coquard I; Anderson DM; Cantuaria G; Colombo N; Garnier-Tixidre C; Gilbert L; Harter P; Hettle R; Lorusso D; Mäenpää J; Marth C; Matsumoto K; Ouwens M; Poveda A; Raspagliesi F; Rhodes K; Rubio Pérez MJ; Shapira-Frommer R; Shikama A; Sikorska M; Moore K; DiSilvestro P
Eur J Cancer; 2021 Nov; 157():415-423. PubMed ID: 34597975
[TBL] [Abstract][Full Text] [Related]
4. A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
Cadoo KA; Grisham RN; O'Cearbhaill RE; Boucicaut NN; Henson M; Iasonos A; Zhou Q; Sarasohn DM; Gallagher J; Kravetz S; Zamarin D; Makker V; Sabbatini PJ; Tew WP; Aghajanian C; Konner JA
Gynecol Oncol; 2020 Apr; 157(1):214-221. PubMed ID: 31959492
[TBL] [Abstract][Full Text] [Related]
5. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
[TBL] [Abstract][Full Text] [Related]
6. Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics.
Dono A; Takayasu T; Ballester LY; Esquenazi Y
J Clin Neurosci; 2020 Dec; 82(Pt A):1-8. PubMed ID: 33317715
[TBL] [Abstract][Full Text] [Related]
7. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
[TBL] [Abstract][Full Text] [Related]
8. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
9. A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered.
Jackson ER; Persson ML; Fish CJ; Findlay IJ; Mueller S; Nazarian J; Hulleman E; van der Lugt J; Duchatel RJ; Dun MD
Neuro Oncol; 2024 May; 26(Supplement_2):S136-S154. PubMed ID: 37589388
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
11. Clinical, qualitative imaging biomarkers, and tumor oxygenation imaging biomarkers for differentiation of midline-located IDH wild-type glioblastomas and H3 K27-altered diffuse midline gliomas in adults.
Sim Y; Choi SH; Lee N; Park YW; Ahn SS; Chang JH; Kim SH; Lee SK
Eur J Radiol; 2024 Apr; 173():111384. PubMed ID: 38422610
[TBL] [Abstract][Full Text] [Related]
12. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
13. A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Villani V; Fabi A; Tanzilli A; Pasqualetti F; Lombardi G; Vidiri A; Gonnelli A; Molinari A; Cantarella M; Bellu L; Terrenato I; Carosi M; Maschio M; Telera SM; Carapella CM; Cognetti F; Paiar F; Zagonel V; Pace A
Future Oncol; 2019 May; 15(15):1717-1727. PubMed ID: 30977687
[No Abstract] [Full Text] [Related]
14. Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location.
Matsuda M; Ishikawa E; Yamamoto T; Akutsu H; Takano S; Matsumura A
J Clin Neurosci; 2017 Jun; 40():115-119. PubMed ID: 28246006
[TBL] [Abstract][Full Text] [Related]
15. Pediatric spinal cord diffuse midline glioma, H3 K27-altered with intracranial and spinal leptomeningeal spread: A case report.
Serrallach BL; Tran BH; Bauer DF; Mohila CA; Adesina AM; McGovern SL; Lindsay HB; Huisman TA
Neuroradiol J; 2022 Oct; 35(5):634-639. PubMed ID: 34989626
[TBL] [Abstract][Full Text] [Related]
16. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
17. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
18. Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J
Asia Pac J Clin Oncol; 2016 Dec; 12(4):323-331. PubMed ID: 27917619
[TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Samol J; Ranson M; Scott E; Macpherson E; Carmichael J; Thomas A; Cassidy J
Invest New Drugs; 2012 Aug; 30(4):1493-500. PubMed ID: 21590367
[TBL] [Abstract][Full Text] [Related]
20. Risk of Adverse Vascular Events in Patients with Malignant Glioma Treated with Bevacizumab Plus Irinotecan: A Systematic Review and Meta-Analysis.
Dong J; Meng X; Li S; Chen Q; Shi L; Jiang C; Cai J
World Neurosurg; 2019 Oct; 130():e236-e243. PubMed ID: 31203059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
